This funding round was led by Bain Capital Life Sciences and SV Health Investors. They join existing investors, including Bill Gates and Access Biotechnology. The money will be used to support several clinical trials.
Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Government-funded initiatives such as the Cancer Moonshot support not only the primary science that often serves as a foundation for medical advances, but also ensure that patients with rare cancers are not overlooked.
Ceryx's device, Cysoni, is designed to pace the heart in rhythm with a person's respiration, so that the heart rate and breathing are synced. This is typically the case for a healthy person, but for someone with heart failure, that link becomes severed, CEO Stuart Plant said.
The DNA currently used in genetic medicines research is synthesized by chemical methods. Ansa Biotechnologies employs faster and less expensive enzymes-based technology, and the startup has raised capital to scale up operations as it prepares to launch its service.
Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to kill bacteria. The Princeton University spinout says its approach could overcome the drug resistance bacteria are developing to currently available products.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The funding round was led by Wellington Management. The company sees its approach as a break from the industry's "disproportionate" focus on dialysis, which is used to treat people with kidney failure.
The company currently operates two centers, one in Cincinnati and the other in Crescent Springs, Kentucky. The Series A funding round led by JAZZ Venture Partners will allow the company to open new locations as well as offering virtual care.
Transformation Capital led the funding round with participation from Andreessen Horowitz, Frist Cressey Ventures, Edward Elmhurst Health, AlleyCorp. The new financing enables Memora to meet commercial demand , drive new partnerships and further improve the care delivery experience, said CEO Manav Sevak.
Ada Health closed its Series B round after a $30 million extension round. International investors Farallon Capital, Red River West and Bertelsmann Investments provided the additional funds. This follows an initial Series B raise of $90 million last May, which was led by Bayer's investment arm.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Series A financing round was led by F-Prime Capital, with existing investors Lerer Hippeau, NextView Ventures and Amplifyher Ventures also participating. The money will be invested in its platform, hiring additional speech-language pathologists, and partnering with more providers and health plans.
Funding for 2021 was up 150% from the previous record of $3.6 billion raised in 2020, according to the 2022 New York Healthcare Innovation Report. Digital health startups in areas including virtual care, patient engagement and mental health captured 87% of funds.
The new infusion brings Wheel’s total funding to $216 million at a time when more companies understand the need to have an on-demand consumer/patient-facing telemedicine service that Wheel possesses but may not necessarily want to build it from the ground up.
The company, which pulls together information on clinicians and researchers, recently closed a funding round led by Altimeter Capital. It plans to use the funds to build out more features and grow its network.
The company is developing a digital therapeutic using VR to manage chronic lower back pain. It recently submitted an application for de novo clearance to the FDA.